Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination with a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk AML, MDS, and MDS/MPN Overlap Syndromes

Next Previous
Search
Trial Profile

A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination with a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk AML, MDS, and MDS/MPN Overlap Syndromes

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Venetoclax (Primary) ; Azacitidine; Blood mononuclear cell therapy; Busulfan; Cedazuridine/decitabine; Fludarabine; Methotrexate; Tacrolimus
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
  • Focus Adverse reactions

    • Most Recent Events

    • 27 Feb 2025 Planned number of patients changed from 100 to 102.
    • 27 Feb 2025 Planned primary completion date changed from 1 Feb 2025 to 1 Dec 2025.
    • 25 Jan 2024 Planned number of patients changed from 78 to 100.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top